Philadelphia’s Jefferson, Einstein exploring merger into 17-hospital system

Jefferson Health and Einstein Healthcare Network, both based in Philadelphia, have announced they’ve signed a letter of intent to merge, the latest in a string of acquisitions by Jefferson.

Since 2015, Jefferson has acquired or merged with five hospitals or health systems, including Philadelphia University, Kennedy Health and Aria Health. Joining with Einstein would be “a perfect match,” according to Jefferson Health and Thomas Jefferson University president and CEO Stephen Klasko, MD, MBA.

"At the new Jefferson our mission is to improve lives. To bring Einstein, with its history, quality and values, into the family brings us closer to that goal," Klasko said in a statement.

The letter of intent between the two systems is non-binding. If the deal is completed, it would combine Jefferson’s 14 hospitals and 50-plus sites of care, including outpatient and urgent care centers, with Einstein’s three hospitals. It would also create one of the largest residency programs in the region.

According to the Philadelphia Inquirer, Jefferson would reach nearly $6 billion in annual revenue with the acquisition and begin to rival the University of Pennsylvania Health System, which has been on its own shopping spree in recent years buying up systems like Princeton HealthCare.

For Einstein, it solves its problem for finding a partner to save the financially-troubled system. It posted a $23 million operating loss in 2017 and had its bond rating downgraded to junk status by Fitch Ratings.

“This merger would enable Einstein to continue living its mission of providing high-quality care with humanity, humility and honor, and also provide opportunities for growth and expansion currently out of the organization's reach,” said Einstein president and CEO Barry Freedman. “Both Jefferson and Einstein are aligned in our belief that together we can redefine how patient care is delivered, how health professionals are educated, how research discoveries are brought to patients, and how the health of our communities can be improved.”

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.